​

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

REGN Stock Forecast

Regeneron Pharmaceuticals (REGN) stock forecast, based on 49 Wall Street analysts, predicts a 12-month average price target of $827.71, with a high of $1,030.00 and a low of $730.00. This represents a 2.48% increase from the last price of $807.65.

$700 $800 $900 $1 $1 $1 High: $1030 Avg: $827.71 Low: $730 Last Closed Price: $807.65

REGN Stock Rating

Regeneron Pharmaceuticals stock's rating consensus is Buy, based on 49 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 34 Buy (69.39%), 15 Hold (30.61%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 49 15 34 0 Strong Sell Sell Hold Buy Strong Buy

REGN Price Target Upside V Benchmarks

TypeNameUpside
StockRegeneron Pharmaceuticals2.48%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts31565
Avg Price Target$833.33$815.60$817.25
Last Closing Price$807.65$807.65$807.65
Upside/Downside3.18%0.98%1.19%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 264149-128
Aug, 264149--27
Jul, 265168--29
Jun, 265168--29
May, 264187--29
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2026Rajesh KumarHSBC$920.00$807.6513.91%13.91%
Aug 17, 2026David RisingerLeerink Partners$824.00$803.482.55%2.02%
Aug 14, 2026Jeffrey WalchBernstein$756.00$799.46-5.44%-6.40%
Aug 03, 2026Guggenheim$1.03K$763.5134.90%27.53%
Jul 31, 2026RBC Capital$737.00$739.50-0.34%-8.75%
Jul 31, 2026Morgan Stanley$758.00$738.822.60%-6.15%
Jul 31, 2026Carter GouldCantor Fitzgerald$795.00$742.597.06%-1.57%
Jul 31, 2026Robert W. Baird$761.00$738.343.07%-5.78%
Jul 31, 2026Wells Fargo$750.00$738.341.58%-7.14%
Jul 21, 2026Yatin SunejaGuggenheim$1.00K$675.7247.99%23.82%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 10, 2026HSBCBuyBuyhold
Sep 01, 2026RBC CapitalSector PerformSector Performhold
Aug 14, 2026BernsteinMarket PerformMarket Performhold
Aug 03, 2026CitigroupNeutralNeutralhold
Jul 31, 2026RBC CapitalSector PerformSector Performhold
Jul 31, 2026Cantor FitzgeraldOverweightOverweighthold
Jul 30, 2026Bank of America SecuritiesBuyBuyhold
Jul 21, 2026GuggenheimBuyBuyhold
Jul 09, 2026Piper SandlerOverweightOverweighthold
Jul 06, 2026Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$30 $40 $50 $60 $70 $80 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$76.40$40.51$37.05$40.90$43.07---
Avg Forecast$71.52$42.60$42.62$45.02$44.51$48.41$56.23$61.14
High Forecast$74.49$45.65$43.60$47.01$52.39$60.93$71.36$66.97
Low Forecast$67.49$40.10$39.84$43.54$34.72$38.38$43.10$56.27
Surprise %6.82%-4.91%-13.07%-9.15%-3.24%---

Revenue Forecast

$11B $13B $15B $16B $18B $20B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$16.07B$12.17B$13.12B$14.20B$14.34B---
Avg Forecast$15.70B$11.86B$12.94B$14.18B$14.63B$15.52B$17.22B$18.20B
High Forecast$16.20B$12.52B$13.07B$14.49B$15.28B$15.58B$17.22B$19.53B
Low Forecast$15.02B$11.33B$12.65B$14.04B$13.90B$15.46B$17.21B$17.08B
Surprise %2.39%2.62%1.37%0.15%-1.95%---

Net Income Forecast

$3B $4B $5B $7B $8B $9B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.08B$4.34B$3.95B$4.41B$4.50B---
Avg Forecast$7.29B$4.49B$3.95B$5.15B$4.36B$4.65B$5.30B$6.95B
High Forecast$8.75B$5.39B$4.74B$5.34B$5.96B$6.93B$8.11B$7.61B
Low Forecast$5.83B$3.59B$3.16B$4.95B$3.95B$4.36B$4.90B$6.40B
Surprise %10.75%-3.36%--14.28%3.36%---

REGN Forecast FAQ

Is Regeneron Pharmaceuticals stock a buy?

Regeneron Pharmaceuticals stock has a consensus rating of Buy, based on 49 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 34 Buy, 15 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Regeneron Pharmaceuticals is a favorable investment for most analysts.

What is Regeneron Pharmaceuticals's price target?

Regeneron Pharmaceuticals's price target, set by 49 Wall Street analysts, averages $827.71 over the next 12 months. The price target range spans from $730 at the low end to $1.03K at the high end, suggesting a potential 2.48% change from the previous closing price of $807.65.

How does Regeneron Pharmaceuticals stock forecast compare to its benchmarks?

Regeneron Pharmaceuticals's stock forecast shows a 2.48% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Regeneron Pharmaceuticals over the past three months?

  • September 2026: 14.29% Strong Buy, 50.00% Buy, 32.14% Hold, 0% Sell, 3.57% Strong Sell.
  • August 2026: 14.81% Strong Buy, 51.85% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 17.24% Strong Buy, 55.17% Buy, 27.59% Hold, 0% Sell, 0% Strong Sell.

What is Regeneron Pharmaceuticals’s EPS forecast?

Regeneron Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $48.41, marking a 12.40% increase from the reported $43.07 in 2025. Estimates for the following years are $56.23 in 2027, and $61.14 in 2028.

What is Regeneron Pharmaceuticals’s revenue forecast?

Regeneron Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $15.52B, reflecting a 8.21% increase from the reported $14.34B in 2025. The forecast for 2027 is $17.22B, and $18.2B for 2028.

What is Regeneron Pharmaceuticals’s net income forecast?

Regeneron Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $4.65B, representing an 3.12% increase from the reported $4.5B in 2025. Projections indicate $5.3B in 2027, and $6.95B in 2028.